Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 5/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | MIF | P14174 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 4/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | GLS | O94925 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23966723 | 0.86 | ALDH1A1 (0.60) | HTTLMNATSHRHSD17B10KMT2A | |
| SCHEMBL13499907 | 0.80 | KMT2A (0.61) | LMNAKMT2AMEN1POLBALDH1A1 | |
| SCHEMBL6215399 | 0.78 | NPC1 (0.60) | HSD17B10KMT2AMEN1POLBALDH1A1 | |
| SCHEMBL9156058 | 0.78 | ALDH1A1 (0.60) | LMNATSHRKMT2AMEN1POLB | |
| SCHEMBL5332558 | 0.78 | ALDH1A1 (0.64) | KMT2AMEN1POLBALDH1A1MIF | |
| SCHEMBL11875075 | 0.77 | NPC1 (0.62) | HTTLMNATSHRHSD17B10KMT2A | |
| SCHEMBL21533438 | 0.77 | ALDH1A1 (0.69) | HTTLMNATSHRHSD17B10POLB | |
| SCHEMBL13453221 | 0.77 | CCNE1 (0.61) | KMT2AMEN1POLBALDH1A1MIF | |
| SCHEMBL1011592 | 0.76 | POLB (0.68) | HTTLMNATSHRHSD17B10KMT2A | |
| SCHEMBL3786921 | 0.75 | POLB (0.66) | HTTLMNAKMT2AMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101948466-B | Asymmetric heterocyclic ring substituent urea compound and preparation method and application thereof | UNIV NANKAI | 2014-04-16 | — | — | CN | disclosed |
| US-20140038978-A1 | HETEROCYCLIC COMPOUNDS AS CCR2B ANTAGONISTS | ASTRAZENECA AB (SE) | 2014-02-06 | — | — | US | disclosed |
| US-20140038978-A1 | HETEROCYCLIC COMPOUNDS AS CCR2B ANTAGONISTS | ASTRAZENECA AB (SE) | 2014-02-06 | — | — | US | disclosed |
| CN-101128427-B | Heterocyclic compounds as ccr2b antagonists | ASTRAZENECA AB | 2013-03-27 | — | — | CN | disclosed |
| US-20110136820-A1 | Heterocyclic Compounds as CCR2 Antagonists | ASTRAZENECA AB (SE) | 2011-06-09 | — | — | US | disclosed |
| US-20110136820-A1 | Heterocyclic Compounds as CCR2 Antagonists | ASTRAZENECA AB (SE) | 2011-06-09 | — | — | US | disclosed |
| US-7906645-B2 | Heterocyclic compounds as ccr2b antagonists | ASTRAZENECA AB (SE) | 2011-03-15 | — | — | US | disclosed |
| US-7906645-B2 | Heterocyclic compounds as ccr2b antagonists | ASTRAZENECA AB (SE) | 2011-03-15 | — | — | US | disclosed |
| CN-101948466-A | Asymmetric heterocyclic ring substituent urea compound and preparation method and application thereof | UNIV NANKAI | 2011-01-19 | — | — | CN | disclosed |
| US-20090099156-A1 | Heterocyclic Compounds as Ccr2b antagonists | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| US-20090099156-A1 | Heterocyclic Compounds as Ccr2b antagonists | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| CN-101128427-A | Heterocyclic compounds as ccr2b antagonists | ASTRAZENECA AB (SE) | 2008-02-20 | — | — | CN | disclosed |
| US-3990879-A | SUBSTITUTED 1-THIADIAZOLYL-3-ARYL-UREAS | ELI LILLY AND COMPANY (US) | 1976-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136820-A1 | Heterocyclic Compounds as CCR2 Antagonists | CCR2, CCR3, CXCR2 | HTT 4425/4885LMNA 1955/4885TSHR 997/4885 |
| US-20140038978-A1 | HETEROCYCLIC COMPOUNDS AS CCR2B ANTAGONISTS | CCR2, CCR3, CXCR2 | HTT 4395/4885LMNA 1933/4885TSHR 1018/4885 |
| US-20090099156-A1 | Heterocyclic Compounds as Ccr2b antagonists | CCR2, CCR3, CXCR2 | HTT 4385/4885LMNA 1858/4885TSHR 973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.